Celldex Therapeutics, Inc.

NASDAQ:CLDX

Biotechnology

Healthcare
$27.55 +0.47%

+$0.16 today

Market cap
$2.16B
Beta
0.93
P/E (TTM)
-7.8
EPS (TTM)
-$4.26
52W Low $19.52High $35.79

Volume 0.68M

Average 0.94M

CLDX Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Celldex Therapeutics, Inc.NASDAQ: CLDX

Cash & Equivalents · Q3 FY2026 · quarter ended Sep 2026

Cash & equivalents falls 25.2% from a year ago

Cash & equivalents stood at $26.95M at the end of Q3 FY2026, down 25.2% from a year earlier and down 43.2% from the prior quarter. Over 3 fiscal years it compounded at -0.6% a year.

Context

  • Cash & equivalents amounted to 3.7% of total assets at the end of Q3 FY2026, down 1.8 pp from a year earlier.
  • Cash & equivalents increased in 2 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -25.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$26.95M-43.2% QoQ
Last fiscal yearDec 2025
$28.87M+1.8% YoY
Year agoSep 2025
$36.04M-25.2% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-25.2%——
1 year+1.8%——
3-year CAGR-0.6%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
28.87M USD
Year-over-year change
+1.8%
4-year CAGR
-7.3%

Cash & Equivalents vs competitors

How CLDX compares with its peers on the latest reported figures

  • CLDX's Sep 2026 cash & equivalents of $26.95M is the 9th highest of the 10 companies compared; the peer median is $66.52M.
  • Its year-over-year change of -25.2% is the 8th highest of 10, against a peer median of -12.5%.
  • Cash & equivalents amounts to 3.7% of total assets for CLDX, versus a peer median of 26.9%.
CLDX Competitors Peer median
Cash & Equivalents for CLDX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NRIXNurix Therapeutics, Inc.Aug 2026$720.24M +818.2%+56.5%60.3%
IMNMImmunome, Inc.Sep 2026$212.84M -21.9%+218.0%42.1%
RCUSArcus Biosciences, Inc.Jun 2026$150M -39.5%+2.5%16.2%
ADAGAdagene Inc.Dec 2025$74.52M -12.5%-19.7%95.2%
MGNXMacroGenics, Inc.Mar 2026$66.52M -54.3%-19.3%30.5%
CMPXCompass Therapeutics, Inc.Mar 2026$55.17M +34.4%-4.3%26.9%
XNCRXencor, Inc.Jun 2026$44.66M +0.5%+0.1%6.2%
AGENAgenus Inc.Mar 2026$35M +89.3%-74.4%18.8%
CLDXCelldex Therapeutics, Inc.Sep 2026$26.95M -25.2%-0.6%3.7%
CGENCompugen Ltd.Mar 2026$12.44M -14.7%+101.6%8.5%
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding CLDX) $66.52M-12.5%+0.1%26.9%

Competitors are the stored peer set for CLDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents39.14M29.43M34.81M28.36M28.87M
Short-term Investments369.11M275.52M386.88M696.93M489.7M
Net Receivables172K347K4.53M700K2.02M
Inventory00000
Other Current Assets005.47M21.18M14.08M
Total Current Assets410.84M317.69M431.69M747.16M534.66M
Property, Plant & Equipment (Net)6.52M7.75M6.64M8.24M7.77M
Goodwill00000
Intangible Assets27.19M27.19M27.19M27.19M27.19M
Long-term Investments00000
Tax Assets00000
Other Non-current Assets104K104K107K9.75M13.36M
Total Non-current Assets33.82M35.04M33.93M45.18M48.32M
Total Assets444.65M352.74M465.63M792.34M582.98M
Account Payables1.23M3.34M3.49M3.27M1.18M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities1.55M990K3.99M942K1.23M
Total Current Liabilities16.53M18.61M31.13M39.5M50.99M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities7.35M5.33M4.4M3.47M4.04M
Total Non-current Liabilities8.65M7.92M5.33M5.83M4.83M
Total Liabilities25.18M26.53M36.46M45.34M55.82M
Common Stock47K47K56K66K67K
Retained Earnings(1.14B)(1.26B)(1.4B)(1.56B)(1.81B)
Accumulated OCI1.89M1.26M3.31M3.31M3.63M
Other Stockholders Equity00000
Minority Interest00000
Total Equity419.48M326.2M429.17M747.01M527.17M
Total Debt3.04M4.03M2.54M3.81M2.34M
Net Debt(36.1M)(25.4M)(32.27M)(24.54M)(26.54M)

Celldex Therapeutics, Inc.

NASDAQ:CLDX

Intrinsic Alpha fair value

Locked

Current Price

$27.55

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.